We're announcing a major milestone: Omic's Digital Patient platform has achieved unprecedented accuracy in predicting clinical trial outcomes through virtual trials.

The Clinical Trial Problem

Clinical trials are the most expensive and time-consuming part of drug development:

  • $2-3 billion average cost per approved drug
  • 90% failure rate in clinical trials
  • 6-10 years from Phase 1 to approval
  • Most failures happen in Phase 2/3, after hundreds of millions invested

The fundamental problem: we don't know how drugs will work in humans until we test them in humans.

Virtual Clinical Trials

Omic's approach uses Digital Patient models to simulate clinical trials computationally:

  1. Build Digital Patients from real patient multi-omics data
  2. Simulate drug administration using mechanistic models
  3. Predict individual responses based on patient biology
  4. Aggregate to trial-level predictions of efficacy and safety

This allows us to run thousands of "virtual trials" before committing to expensive human studies.

Validation Results

We retrospectively tested our virtual trial predictions against actual clinical trial outcomes:

Metric Our Prediction Industry Average
Phase 2 success prediction 82% accuracy ~30% hit rate
Response rate prediction ±8% error ±25% error
Safety signal detection 91% sensitivity 60-70%
Biomarker identification 76% validated ~40%

These results were validated across 50+ historical trials in oncology and autoimmune disease.

How It Works

Our virtual trial system integrates:

  • Population modeling: Generate realistic virtual cohorts matching trial inclusion criteria
  • PK/PD simulation: Predict drug concentrations and pharmacological effects
  • Response modeling: Use Digital Patient biology to predict who responds
  • Statistical analysis: Apply same endpoints and analyses as real trials

The key innovation is the biological fidelity of our Digital Patients—they respond to simulated drugs based on their actual molecular biology, not statistical averages.

Implications

If virtual trials can reliably predict clinical outcomes, the implications are profound:

  1. Kill failures earlier: Identify likely failures before expensive Phase 2/3 trials
  2. Optimize trial design: Select right dose, duration, and endpoints upfront
  3. Identify responders: Enrich trials with patients likely to respond
  4. Reduce costs: Each percentage point improvement in success rate saves billions industry-wide

What's Next

We're now applying virtual trials prospectively to our internal pipeline programs:

  • ONC-001: Virtual Phase 2 completed, guiding clinical strategy
  • HEM-001: Virtual trials informing patient selection strategy
  • CVD-001: Using virtual trials to optimize compound selection

We're also exploring partnerships with pharmaceutical companies interested in applying virtual trials to their pipelines.

For partnership inquiries about virtual clinical trials, contact partnerships@omic.ai

Omic - Building Biological Superintelligence to End Disease